Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 1999

View Archived Issues

MUC1 mucin expression related to T-cell activation

Reticulose enhances efficacy of HAART cocktail in two case studies

Amrad to distribute PathoGenesis's inhalable CF treatment in Australia

Bayer to acquire OSI's diagnostics business

Patent licensed to Endorex/Elan joint venture covers mucosal delivery systems

Preliminary phase III results disappointing for Anogesic as anal fissure therapy

Gliatech soon to begin phase II Perceptin trials in ADHD

Abbott acquires anesthesia/analgesia products from Glaxo Wellcome

Abbott and Alza update merger proceedings

Pozen licenses migraine prophylactic from Roche

AxyS and Merck extend osteoporosis collaboration

Once-weekly Fosamax as effective as daily dosing

Xenova's IND for multidrug resistance modulator gets FDA approval

Novel antitumor agents for both leukemias and solid tumors discovered by Taiwanese scientists

Calcimimetics and calcilytics designed at NPS

Sanofi-Synthelabo pipeline includes compounds with neurotrophic/neuroprotective effects

Calcium channel blockers with piperidine structure synthesized at NeuroSearch

Abbott's new LHRH antagonists, pharmaceutical compositions and use

Korean investigators disclose new hepatoprotective agents

Methylenecyclopropane nucleoside analogues as effective agents for CMV infections

Eradication of H. pylori infection obtained with low doses of new cephem

Azimilide pharmacokinetics not significantly affected by severe renal impairment

Pharmacokinetics and pharmacodynamics of eniporide assessed over wide dose range

WHI-D12 is a potent and selective inhibitor of Bruton's tyrosine kinase

New acylfulvene analogues with clinical potential identified by MGI Pharma

Geldanamycin derivative with selective activity against breast cancer developed at Sloan-Kettering

Gender does not affect PK of Sch-58235: results presented at 1999 AAPS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...